Expanding Clinical Spectrum of Anti-GQ1b Antibody Syndrome: A Review | Ophthalmology | JAMA Neurology | JAMA Network
[Skip to Navigation]
Review
May 13, 2024

Expanding Clinical Spectrum of Anti-GQ1b Antibody Syndrome: A Review

Author Affiliations
  • 1Department of Neurology, Korea University Medical Center, Seoul, South Korea
  • 2Neurotology and Neuro-ophthalmology Laboratory, Korea University Anam Hospital, Seoul, South Korea
  • 3Biomedical Research Institute, Seoul National University Bundang Hospital, Seongnam, South Korea
  • 4Dizziness Center, Clinical Neuroscience Center, Department of Neurology, Seoul National University Bundang Hospital, Seongnam, South Korea
  • 5Deparment of Neurology, Seoul National University College of Medicine, Seoul, South Korea
  • 6Department of Neurology, Pusan National University Hospital, Pusan National University School of Medicine and Biomedical Research Institute, Pusan, South Korea
JAMA Neurol. Published online May 13, 2024. doi:10.1001/jamaneurol.2024.1123
Abstract

Importance  The discovery of the anti-GQ1b antibody has expanded the nosology of classic Miller Fisher syndrome to include Bickerstaff brainstem encephalitis, Guillain-Barré syndrome with ophthalmoplegia, and acute ophthalmoplegia without ataxia, which have been brought under the umbrella term anti-GQ1b antibody syndrome. It seems timely to define the phenotypes of anti-GQ1b antibody syndrome for the proper diagnosis of this syndrome with diverse clinical presentations. This review summarizes these syndromes and introduces recently identified subtypes.

Observations  Although ophthalmoplegia is a hallmark of anti-GQ1b antibody syndrome, recent studies have identified this antibody in patients with acute vestibular syndrome, optic neuropathy with disc swelling, and acute sensory ataxic neuropathy of atypical presentation. Ophthalmoplegia associated with anti-GQ1b antibody positivity is complete in more than half of the patients but may be monocular or comitant. The prognosis is mostly favorable; however, approximately 14% of patients experience relapse.

Conclusions and Relevance  Anti-GQ1b antibody syndrome may present diverse neurological manifestations, including ophthalmoplegia, ataxia, areflexia, central or peripheral vestibulopathy, and optic neuropathy. Understanding the wide clinical spectrum may aid in the differentiation and management of immune-mediated neuropathies with multiple presentations.

×